IOL Chemicals & Pharmaceuticals Downgraded to 'Sell' by MarketsMOJO: Poor Growth and Institutional Investors Decrease Stake

IOL Chemicals & Pharmaceuticals, a smallcap company in the chemicals industry, has recently been downgraded to a 'Sell' by MarketsMOJO on June 24, 2024. This decision was based on the company's poor long-term growth, negative results in the last quarter, and falling participation by institutional investors. According to MarketsMOJO, IOL Chemicals & Pharmaceuticals has shown a slow growth rate of 15.09% in operating profit over the last 5 years. In addition, the company's profits have declined significantly in the last quarter, with PAT(HY) at Rs 50.70 crore showing a decrease of -42.75% and PBT LESS OI(Q) at Rs 29.68 crore falling by -40.7%. The company's net sales have also seen a decline of -9.0% in the last quarter. Moreover, institutional investors have decreased their stake in the company by -0.84% in the previous quarter, collectively holding only 1.71% of the company. This is a cause for concern as institutional investors are known for their ability to analyze company fundamentals. In terms of performance, IOL Chemicals & Pharmaceuticals has underperformed the BSE 500 index in the last 3 years, 1 year, and 3 months, with a return of -3.12%. The technical trend for the stock is also sideways, indicating no clear price momentum. The stock has generated a return of -1.35% since its downgrade on June 24, 2024. On a positive note, the company has a low debt to equity ratio of 0.10 times, which is below the industry average. It also has an attractive valuation with a price to book value of 1.5, trading at a discount compared to its historical valuations. However, despite this, the stock's return of -3.12% in the last year is still lower than its profits, which have fallen by -3.3%. In conclusion, based on the recent downgrade by MarketsMOJO and the company's poor long-term growth, negative results in the last quarter, and falling participation by institutional investors, it may be wise for investors to consider selling their shares in IOL Chemicals & Pharmaceuticals.